Abstract
Recent advances in the detection and treatment of cancer have led to a vast improvement in cancer survival, but this comes at the cost of adverse cardiovascular effects. Toxicities associated with cancer therapies include heart failure (HF) and cardiomyopathy. Although the pathophysiology and mechanism of cancer therapy-mediated cardiotoxicity is well described, the management strategies for the prevention and treatment of HF in these patients are not clearly defined. In this article, we discuss the definitions, pathophysiology, mechanisms, imaging, prevention, and treatment of HF in cancer patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
